
ONCS
OncoSec Medical Inc
$0.28
0.00%Name
OncoSec Medical Inc
Website
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
Categories
Commercial ServicesMiscellaneous Commercial ServicesHealth ServicesMedical/Nursing ServicesManufacturingPharmaceutical Preparation Manufacturing
CEO
Daniel O'Connor
Employees
88,300
Description
oncosec is a san diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients. our technology, immunopulse™, is designed to enhance the local delivery and uptake of dna-based immune-targeting agents, such as il-12. clinical trials of immunopulse™ il-12 demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. our lead program, immunopulse™ il-12, is currently in phase ii development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. to date, study results have laid the groundwork for the expansion into new dna-encoded therapeutic candidates and tumor indications. we ar
Market Cap
$1.65M
52 Week High
$0.28
PE Ratio
-
52 Week Low
-
EPS
-
Shares Outstanding
5.96M
Dividend Yield
-
Dividend Per Share
-
Name
OncoSec Medical Inc
Website
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
Categories
Commercial ServicesMiscellaneous Commercial ServicesHealth ServicesMedical/Nursing ServicesManufacturingPharmaceutical Preparation Manufacturing
CEO
Daniel O'Connor
Employees
88,300
Description
oncosec is a san diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients. our technology, immunopulse™, is designed to enhance the local delivery and uptake of dna-based immune-targeting agents, such as il-12. clinical trials of immunopulse™ il-12 demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. our lead program, immunopulse™ il-12, is currently in phase ii development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. to date, study results have laid the groundwork for the expansion into new dna-encoded therapeutic candidates and tumor indications. we ar